Novo Nordisk A/S (NONOF)
OTCMKTS
· Delayed Price · Currency is USD
65.55
-0.15 (-0.23%)
May 15, 2025, 4:00 PM EDT
Novo Nordisk Employees
As of December 31, 2024, Novo Nordisk had 77,349 total employees, including 76,302 full-time and 1,047 part-time employees. The number of employees increased by 13,030 or 20.26% compared to the previous year.
Employees
77,349
Change (1Y)
13,030
Growth (1Y)
20.26%
Revenue / Employee
$567,426
Profits / Employee
$195,821
Market Cap
289.00B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
CytoDyn | 9 |
Elite Pharmaceuticals | 64 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Novo Nordisk News
- 1 day ago - Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs - Benzinga
- 1 day ago - Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs - Benzinga
- 1 day ago - Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing - Investor's Business Daily
- 1 day ago - This biotech’s stock rockets on oral obesity drug partnership with Wegovy parent - MarketWatch
- 1 day ago - Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases - WSJ
- 1 day ago - Novo Nordisk in pact with Septerna for oral obesity drugs - Seeking Alpha
- 1 day ago - Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - Reuters
- 2 days ago - Lexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo Nordisk - Seeking Alpha